Park Medi World Limited (PARKHOSPS) Fair Value & Analysis
Healthcare · IN · Market cap ₹124B
Fair value as of: Jul 3, 2026
From 24 valuation models · updated today
Share price +2.7% over the past month.
Price vs Fair Value (7 months)
7‑month range ₹143.92 – ₹299.30 · fair‑value band ₹81.69 – ₹153.21 · the ₹294.80 price screens above the ₹119.52 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Park Medi World Limited (PARKHOSPS) currently trades at ₹294.80, while our model-based Fair Value estimate is ₹119.52 — implying the stock looks roughly 59.5% overvalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Park Medi World Limited generated revenue of ₹16.8B at a net margin of 15.4%. Revenue grew 30.1% year over year. It earns a return on equity of 16.9%. Net debt stands at ₹5.2B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.
Revenue & earnings trend
FY2023 – FY2026 · reported fiscal years
Park Medi World Limited reported revenue of ₹16.8B in FY2026 versus ₹12.5B in FY2023, a compound +10.3%/yr. Reported net income was ₹2.6B in FY2026, compounding +5.5%/yr from FY2023.
Is PARKHOSPS fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.67 MYR | 3.08 MYR | -64% |
| IHHHF IHHHF | $1.71 | $0.7400 | -57% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Park Medi World Limited (PARKHOSPS) undervalued?
What is the fair value of PARKHOSPS?
What is the quality score of PARKHOSPS?
What is the revenue of Park Medi World Limited (PARKHOSPS)?
What is the net profit margin of PARKHOSPS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.